AYTU BioPharma
AYTU
21 hedge funds and large institutions have $1.18M invested in AYTU BioPharma in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 17 closing their positions.
14.66% more ownership
Funds ownership: 0.64% → 15.3% (+15%)
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
23% less capital invested
Capital invested by funds: $1.54M → $1.18M (-$358K)
42% less funds holding
Funds holding: 36 → 21 (-15)
88% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$795K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$138K |
| 3 |
BTI
Blue Trust Inc
Alpharetta,
Georgia
|
+$15.5K |
| 4 |
Prudential Financial
Newark,
New Jersey
|
+$15.2K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$14.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$225K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$184K |
| 3 |
Renaissance Technologies
New York
|
-$168K |
| 4 |
ACM
Allred Capital Management
Dallas,
Texas
|
-$23.6K |
| 5 |
State Street
Boston,
Massachusetts
|
-$18.5K |
AYTU Hedge Fund Activity: Q1 2023 in Review
21 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q1 2023, worth a combined $1.18M — down 23% from $1.54M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of AYTU and 2 opened new positions — a net loss of 15 holders — while 9 trimmed existing stakes and 7 added.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $795K. The largest seller was Millennium Management, exiting entirely with an estimated $225K sold.
- 21 institutional investors held AYTU BioPharma (AYTU) as of Q1 2023, down from 36 in Q4 2022.
- Funds reported $1.18M of AYTU BioPharma stock for Q1 2023, down 23% quarter-over-quarter.
- 2 funds opened new AYTU BioPharma positions in Q1 2023 and 17 closed out, a net change of -15 holders.
- The largest AYTU BioPharma buyer in Q1 2023 was Nantahala Capital Management, an estimated $795K added.
- The largest AYTU BioPharma seller in Q1 2023 was Millennium Management, an estimated $225K sold.
Based on aggregated 13F filings for Q1 2023.